184 related articles for article (PubMed ID: 37442901)
1. Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study.
Xiao T; Jiao R; Yang S; Wang Y; Bai X; Zhou J; Li R; Wang L; Yang H; Yao Y; Deng K; Gong F; Pan H; Duan L; Zhu H
Endocrine; 2023 Nov; 82(2):368-378. PubMed ID: 37442901
[TBL] [Abstract][Full Text] [Related]
2. Acromegaly and cancer risk: a cohort study in Sweden and Denmark.
Baris D; Gridley G; Ron E; Weiderpass E; Mellemkjaer L; Ekbom A; Olsen JH; Baron JA; Fraumeni JF
Cancer Causes Control; 2002 Jun; 13(5):395-400. PubMed ID: 12146843
[TBL] [Abstract][Full Text] [Related]
3. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
4. Thyroid cancer is the most common cancer associated with acromegaly.
Gullu BE; Celik O; Gazioglu N; Kadioglu P
Pituitary; 2010 Sep; 13(3):242-8. PubMed ID: 20217483
[TBL] [Abstract][Full Text] [Related]
5. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
6. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
7. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.
Carosi G; Mangone A; Sala E; Del Sindaco G; Mungari R; Cremaschi A; Ferrante E; Arosio M; Mantovani G
Eur J Endocrinol; 2021 Jul; 185(2):289-297. PubMed ID: 34081617
[TBL] [Abstract][Full Text] [Related]
8. Increased thyroid cancer risk in acromegaly.
Dagdelen S; Cinar N; Erbas T
Pituitary; 2014 Aug; 17(4):299-306. PubMed ID: 23836362
[TBL] [Abstract][Full Text] [Related]
9. The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer.
Ruchala M; Skiba A; Gurgul E; Uruski P; Wasko R; Sowinski J
Neuro Endocrinol Lett; 2009; 30(3):382-6. PubMed ID: 19855364
[TBL] [Abstract][Full Text] [Related]
10. Cancer Risk and its Association With Diabetes Mellitus in Patients With Acromegaly: A Two Center-based Study.
Xiao ZH; Wang C; Wang Y; Yuan SK; Huang C; Chen RF; Li Y
Endocr Pract; 2023 Sep; 29(9):699-704. PubMed ID: 37343764
[TBL] [Abstract][Full Text] [Related]
11. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
12. Acromegaly, growth hormone and cancer risk.
Renehan AG; Brennan BM
Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):639-57. PubMed ID: 18971124
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.
Gasperi M; Martino E; Manetti L; Arosio M; Porretti S; Faglia G; Mariotti S; Colao AM; Lombardi G; Baldelli R; Camanni F; Liuzzi A;
J Endocrinol Invest; 2002 Mar; 25(3):240-5. PubMed ID: 11936466
[TBL] [Abstract][Full Text] [Related]
14. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
15. Follow, consider, and catch: second primary tumors in acromegaly patients.
Oguz SH; Firlatan B; Sendur SN; Dagdelen S; Erbas T
Endocrine; 2023 Apr; 80(1):160-173. PubMed ID: 36517649
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with thyroid nodular disease in acromegalic patients: A case-cohort study in a tertiary center.
Vargas-Ortega G; Romero-Gameros CA; Rendón-Macias ME; Balcázar-Hernández L; Sosa-Eroza E; Mercado M; de Los Monteros-Sánchez ALE; Pérez-Aguilar B; Paredes-Manjarrez C; Reyes-Olhagaray FB; Serrano-Ramírez DL; la Cruz EVM; González-Virla B
Growth Horm IGF Res; 2021; 60-61():101431. PubMed ID: 34740022
[TBL] [Abstract][Full Text] [Related]
17. The Incidence of Cancer Among Acromegaly Patients: Results From the German Acromegaly Registry.
Petroff D; Tönjes A; Grussendorf M; Droste M; Dimopoulou C; Stalla G; Jaursch-Hancke C; Mai M; Schopohl J; Schöfl C
J Clin Endocrinol Metab; 2015 Oct; 100(10):3894-902. PubMed ID: 26244491
[TBL] [Abstract][Full Text] [Related]
18. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970-2016.
Orme S; McNally R; James PW; Davis J; Ayuk J; Higham C; Wass J;
Clin Endocrinol (Oxf); 2024 Jun; 100(6):558-564. PubMed ID: 38652736
[TBL] [Abstract][Full Text] [Related]
19. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
[TBL] [Abstract][Full Text] [Related]
20. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study.
Colao A; Grasso LFS; Di Cera M; Thompson-Leduc P; Cheng WY; Cheung HC; Duh MS; Neary MP; Pedroncelli AM; Maamari R; Pivonello R
J Endocrinol Invest; 2020 Apr; 43(4):529-538. PubMed ID: 31741320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
